glp-1 drugs weight loss effectiveness without diabetes leave users low on key nutrients, study finds GLP-1 drugs are often misunderstood.

Lawrance R, Degtyarev E, Griffiths P et al (2020) What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials

SELECT CVOT trial investigated the cardiovascular safety of semaglutide 2.4 mg therapy once a week in a group of 17,605 overweight or obese adults over the age of 45 with no history of T2DM

At present, several GLP-1 analogs have joined the class, such as exenatide, liraglutide, dulaglutide, semaglutide and tirzepatide [1]

Accordingly, a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) represents a contraindication to the use of GLP-1RAs and are exclusion criteria for participation in clinical trials with GLP-1RAs

Differential patterns of neuronal activation in the brainstem and hypothalamus following peripheral injection of GLP-1, oxyntomodulin and lithium chloride in mice detected by manganese-enhanced magnetic resonance imaging (MEMRI) Neuroimage

Ideally the group needed to find a way to make it last for 24 hours and be administered as one injection weekly